viewKazia Therapeutics Ltd

Kazia Therapeutics to present on phase II study of GDC-0084 in glioblastoma at Neuro Oncology meeting in France

The company is in discussion with clinicians and potential collaborators regarding the strategy for further development of GDC-0084 in glioblastoma.

Kazia Therapeutics Ltd - Kazia Therapeutics Ltd to present at the 14th annual Neuro Oncology meeting in France
Kazia’s lead program is GDC-0084, which is being developed to treat a common and aggressive form of brain cancer

Kazia Therapeutics Ltd (ASX:KZA) will provide a poster presentation concerning its ongoing phase II study of GDC-0084 in glioblastoma during the 14th annual meeting of the European Association of Neuro Oncology (EANO) in France from September 19-22.

The poster will be presented at the meeting in Lyon by Professor Patrick Wen from Dana-Farber Cancer Institute and Dr Jeremy Simpson from Kazia.

“Exciting landmark”

Kazia's chief executive officer James Garner said: “This is a ‘study design’ poster which describes our approach to the development of GDC-0084, which provides us with a powerful opportunity to engage with clinicians and potential partners.

"We expect to be able to share initial data from this study in November, which will be an exciting landmark for the GDC-0084 program.

“In the meantime, our participation in EANO helps to raise awareness of the study in advance of that initial data read-out.”


The company has had another abstract accepted for presentation at the 24th annual meeting of the Society for Neuro-Oncology (SNO) which will take place in Phoenix, Arizona, from November 20-24.

The initial data from the ongoing phase-II study of GDC-0084 in glioblastoma will be presented at this meeting.

In addition, an abstract on Dana-Farber Cancer Center’s trial of GDC-0084 in breast cancer brain metastases has been accepted to the San Antonia Breast Cancer Symposium in San Antonio, Texas from December 10-14.

Several manuscripts have been submitted to academic journals relating to GDC-0084 both by Kazia as well as partners and collaborators.

It is expected that the next step for GDC-0084 will be a pivotal study to seek marketing authorization from regulatory agencies such as the US FDA.

Quick facts: Kazia Therapeutics Ltd

Price: 0.445 AUD

Market: ASX
Market Cap: $32.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Kazia Therapeutics releases data from study of GDC-0084 into...

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the release of positive key interim data from the company's ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. Dr Garner explains...

on 25/11/19

2 min read